ArticleJournal of orthopaedic translation2026
Activation of α2-adrenergic receptors as a therapeutic strategy for immune rejection in post-surgery osteosarcoma recurrence treatment.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
- Advancing the continuum of orthopaedic translation: Mechanistic insight, regenerative innovation, and converging technologies.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical treatment of Osteosarcoma (OS) faces major barriers due to the risk of tumor recurrence. Immunotherapy utilizing immune checkpoint blockade (ICB) antibodies has exhibited promise in inducing tumor rejection and providing clinical benefits for patients among various tumor types. However, tumors often develop resistance to immune rejection. Given the limitations of current therapies, there is an urgent need to explore novel therapeutic strategies to enhance anti-tumor immunity and prevent recurrence. This study aims to investigate the potential of α2-adrenergic receptor (α2-AR) agonists, delivered via a thermo-sensitive hydrogel (PLGA-PEG-PLGA), as a therapeutic strategy to combat immune rejection and tumor recurrence in osteosarcoma. Methods: In this study, we investigated the anti-tumor effects of α2-AR agonists using a thermo-sensitive PLGA-PEG-PLGA hydrogel as a drug delivery system. The hydrogel was loaded with the α2-AR agonist UK14,304 and evaluated for its efficacy and biosafety Results: We evaluated the anti-tumor effects of α2-AR agonists (specifically UK14,304) loaded into a thermo-sensitive PLGA-PEG-PLGA hydrogel both Conclusion: Overall, our results demonstrate that α2-AR agonists may serve as a potential drug for a prospective drug delivery system in the post-surgical management of OS. Significance statement: This study highlights the therapeutic efficacy of α2-AR agonists in osteosarcoma treatment through a novel drug delivery system, suggesting their potential to enhance anti-tumor immune responses by modulating CD8 The translational potential of this article: The findings of this study present a promising translational potential by demonstrating the efficacy of α2-AR agonists in enhancing anti-tumor immunity in OS, potentially paving the way for targeted immunotherapies in post-surgical management to combat tumor recurrence and resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.